← Chongqing Zhifei Bio Products overview

Chongqing Zhifei Bio Products vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Chongqing Zhifei Bio Products (300122.CS)

Q3 202620 Jul – 9 Sep 2026

▲3▼1

Zhifei pushes buyback and new vaccine pipeline despite losses

Share buyback signals confidence Zhifei plans to buy back 150-300 million yuan of its own shares, at up to 18.22 yuan each, for staff incentives. Buybacks shrink the number of shares and show management thinks the stock is cheap, which supports the price.
The buyback is a direct capital action aimed at supporting the share price.
Three new vaccine candidates enter trials Its units won Chinese regulator acceptance or approval to test a nasal spray RSV vaccine, a freeze-dried rabies vaccine and a recombinant rotavirus vaccine. These add future products, but the company says they won't affect near-term results.
Pipeline progress is the main new operating news and supports long-term growth expectations.
Semaglutide injection registration accepted Zhifei's controlling subsidiary had its production registration application for semaglutide injection accepted by the drug regulator. This moves the company beyond vaccines into a fast-growing weight-loss and diabetes market, though approval and sales are still uncertain.
It is a new regulatory step that broadens the product story beyond vaccines.
First-quarter loss shows weak core business The company reported first-quarter 2026 revenue of 2.15 billion yuan and a net loss of 388 million yuan. That loss is the real counterweight: buybacks and pipeline news don't fix current weak earnings, so the stock's rise rests on future hopes.
It gives the fair counterweight that current profits are still negative.

August 202620 Jul – 9 Sep 2026

▲3▼1

Zhifei pushes buyback and new vaccine pipeline despite losses

Share buyback signals confidence Zhifei plans to buy back 150-300 million yuan of its own shares, at up to 18.22 yuan each, for staff incentives. Buybacks shrink the number of shares and show management thinks the stock is cheap, which supports the price.
The buyback is a direct capital action aimed at supporting the share price.
Three new vaccine candidates enter trials Its units won Chinese regulator acceptance or approval to test a nasal spray RSV vaccine, a freeze-dried rabies vaccine and a recombinant rotavirus vaccine. These add future products, but the company says they won't affect near-term results.
Pipeline progress is the main new operating news and supports long-term growth expectations.
Semaglutide injection registration accepted Zhifei's controlling subsidiary had its production registration application for semaglutide injection accepted by the drug regulator. This moves the company beyond vaccines into a fast-growing weight-loss and diabetes market, though approval and sales are still uncertain.
It is a new regulatory step that broadens the product story beyond vaccines.
First-quarter loss shows weak core business The company reported first-quarter 2026 revenue of 2.15 billion yuan and a net loss of 388 million yuan. That loss is the real counterweight: buybacks and pipeline news don't fix current weak earnings, so the stock's rise rests on future hopes.
It gives the fair counterweight that current profits are still negative.

Latest20 Jul – 9 Sep 2026

▲3▼1

Zhifei pushes buyback and new vaccine pipeline despite losses

Share buyback signals confidence Zhifei plans to buy back 150-300 million yuan of its own shares, at up to 18.22 yuan each, for staff incentives. Buybacks shrink the number of shares and show management thinks the stock is cheap, which supports the price.
The buyback is a direct capital action aimed at supporting the share price.
Three new vaccine candidates enter trials Its units won Chinese regulator acceptance or approval to test a nasal spray RSV vaccine, a freeze-dried rabies vaccine and a recombinant rotavirus vaccine. These add future products, but the company says they won't affect near-term results.
Pipeline progress is the main new operating news and supports long-term growth expectations.
Semaglutide injection registration accepted Zhifei's controlling subsidiary had its production registration application for semaglutide injection accepted by the drug regulator. This moves the company beyond vaccines into a fast-growing weight-loss and diabetes market, though approval and sales are still uncertain.
It is a new regulatory step that broadens the product story beyond vaccines.
First-quarter loss shows weak core business The company reported first-quarter 2026 revenue of 2.15 billion yuan and a net loss of 388 million yuan. That loss is the real counterweight: buybacks and pipeline news don't fix current weak earnings, so the stock's rise rests on future hopes.
It gives the fair counterweight that current profits are still negative.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.